BridgeBio Pharma (NASDAQ:BBIO) Downgraded by Jefferies Financial Group
Jefferies Financial Group cut shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) from a buy rating to a hold rating in a research note published on Monday, Marketbeat reports. They currently have $33.00 price target on the stock, up from their prior price target of $24.00. The analysts noted that the move was a valuation […]